Clinical benefit and risk of death with endocrine therapy in ovarian cancer

A comprehensive review and meta-analysis

Laura Paleari, Sara Gandini, Nicoletta Provinciali, Matteo Puntoni, Nicoletta Colombo, Andrea DeCensi

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background Steroid hormones promote epithelial ovarian cancer (EOC) growth and their receptor expression is associated with disease outcome. Hormone therapy is frequently used in pretreated EOC, but the magnitude of activity overall and by specific agents or tumor characteristics is unknown. Methods Clinical Benefit Rates (CBR) and deaths from clinical trials of endocrine agents were meta-analyzed. Summary estimates of CBR (SCBR) and Odd Ratio for death (SOR) were calculated according with type of drug, ER and PgR status, platinum resistance, line of therapy, tumor grade and tamoxifen dose. Results Fifty-three trials in 2490 patients were analyzed. Overall, SCBR was 41% (95%CI, 0.34–0.48) for any endocrine treatment, 43% (95%CI, 0.30–0.56) for tamoxifen, 39% (95%CI, 0.29–0.50) for aromatase inhibitors and 37% (95%CI, 0.26–0.48) for progestins. The SCBR for ER + and/or PgR + tumors was 46% (95%CI, 0.34–0.57) versus 37% (95%CI, 0.27–0.48) in tumors with unknown receptors and 55% in platinum sensitive (95%CI, 0.28–0.80) versus 40% (95%CI, 0.29–0.51) in platinum resistant tumors The SOR for death calculated from 6 out of 9 randomized clinical trials (RCTs) showed a reduced mortality with endocrine therapy (SOR = 0.69, 95%CI, 0.50–0.97), with a possible tendency for a greater effect in first line and low grade tumors. The overall quality of the RCTs was low. Conclusions The activity of endocrine therapy in advanced EOC is worth considering and seems to support large properly designed randomized trials in the first treatment of hormone sensitive EOC.

Original languageEnglish
Pages (from-to)504-513
Number of pages10
JournalGynecologic Oncology
Volume146
Issue number3
DOIs
Publication statusPublished - Sep 1 2017

Fingerprint

Ovarian Neoplasms
Meta-Analysis
Platinum
Neoplasms
Hormones
Tamoxifen
Therapeutics
Randomized Controlled Trials
Aromatase Inhibitors
Mortality
Progestins
Odds Ratio
Steroids
Clinical Trials
Ovarian epithelial cancer
Growth
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynaecology

Cite this

Clinical benefit and risk of death with endocrine therapy in ovarian cancer : A comprehensive review and meta-analysis. / Paleari, Laura; Gandini, Sara; Provinciali, Nicoletta; Puntoni, Matteo; Colombo, Nicoletta; DeCensi, Andrea.

In: Gynecologic Oncology, Vol. 146, No. 3, 01.09.2017, p. 504-513.

Research output: Contribution to journalArticle

Paleari, Laura ; Gandini, Sara ; Provinciali, Nicoletta ; Puntoni, Matteo ; Colombo, Nicoletta ; DeCensi, Andrea. / Clinical benefit and risk of death with endocrine therapy in ovarian cancer : A comprehensive review and meta-analysis. In: Gynecologic Oncology. 2017 ; Vol. 146, No. 3. pp. 504-513.
@article{f65bb6bc119c422bb3d4313b594d5c07,
title = "Clinical benefit and risk of death with endocrine therapy in ovarian cancer: A comprehensive review and meta-analysis",
abstract = "Background Steroid hormones promote epithelial ovarian cancer (EOC) growth and their receptor expression is associated with disease outcome. Hormone therapy is frequently used in pretreated EOC, but the magnitude of activity overall and by specific agents or tumor characteristics is unknown. Methods Clinical Benefit Rates (CBR) and deaths from clinical trials of endocrine agents were meta-analyzed. Summary estimates of CBR (SCBR) and Odd Ratio for death (SOR) were calculated according with type of drug, ER and PgR status, platinum resistance, line of therapy, tumor grade and tamoxifen dose. Results Fifty-three trials in 2490 patients were analyzed. Overall, SCBR was 41{\%} (95{\%}CI, 0.34–0.48) for any endocrine treatment, 43{\%} (95{\%}CI, 0.30–0.56) for tamoxifen, 39{\%} (95{\%}CI, 0.29–0.50) for aromatase inhibitors and 37{\%} (95{\%}CI, 0.26–0.48) for progestins. The SCBR for ER + and/or PgR + tumors was 46{\%} (95{\%}CI, 0.34–0.57) versus 37{\%} (95{\%}CI, 0.27–0.48) in tumors with unknown receptors and 55{\%} in platinum sensitive (95{\%}CI, 0.28–0.80) versus 40{\%} (95{\%}CI, 0.29–0.51) in platinum resistant tumors The SOR for death calculated from 6 out of 9 randomized clinical trials (RCTs) showed a reduced mortality with endocrine therapy (SOR = 0.69, 95{\%}CI, 0.50–0.97), with a possible tendency for a greater effect in first line and low grade tumors. The overall quality of the RCTs was low. Conclusions The activity of endocrine therapy in advanced EOC is worth considering and seems to support large properly designed randomized trials in the first treatment of hormone sensitive EOC.",
author = "Laura Paleari and Sara Gandini and Nicoletta Provinciali and Matteo Puntoni and Nicoletta Colombo and Andrea DeCensi",
year = "2017",
month = "9",
day = "1",
doi = "10.1016/j.ygyno.2017.06.036",
language = "English",
volume = "146",
pages = "504--513",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Clinical benefit and risk of death with endocrine therapy in ovarian cancer

T2 - A comprehensive review and meta-analysis

AU - Paleari, Laura

AU - Gandini, Sara

AU - Provinciali, Nicoletta

AU - Puntoni, Matteo

AU - Colombo, Nicoletta

AU - DeCensi, Andrea

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Background Steroid hormones promote epithelial ovarian cancer (EOC) growth and their receptor expression is associated with disease outcome. Hormone therapy is frequently used in pretreated EOC, but the magnitude of activity overall and by specific agents or tumor characteristics is unknown. Methods Clinical Benefit Rates (CBR) and deaths from clinical trials of endocrine agents were meta-analyzed. Summary estimates of CBR (SCBR) and Odd Ratio for death (SOR) were calculated according with type of drug, ER and PgR status, platinum resistance, line of therapy, tumor grade and tamoxifen dose. Results Fifty-three trials in 2490 patients were analyzed. Overall, SCBR was 41% (95%CI, 0.34–0.48) for any endocrine treatment, 43% (95%CI, 0.30–0.56) for tamoxifen, 39% (95%CI, 0.29–0.50) for aromatase inhibitors and 37% (95%CI, 0.26–0.48) for progestins. The SCBR for ER + and/or PgR + tumors was 46% (95%CI, 0.34–0.57) versus 37% (95%CI, 0.27–0.48) in tumors with unknown receptors and 55% in platinum sensitive (95%CI, 0.28–0.80) versus 40% (95%CI, 0.29–0.51) in platinum resistant tumors The SOR for death calculated from 6 out of 9 randomized clinical trials (RCTs) showed a reduced mortality with endocrine therapy (SOR = 0.69, 95%CI, 0.50–0.97), with a possible tendency for a greater effect in first line and low grade tumors. The overall quality of the RCTs was low. Conclusions The activity of endocrine therapy in advanced EOC is worth considering and seems to support large properly designed randomized trials in the first treatment of hormone sensitive EOC.

AB - Background Steroid hormones promote epithelial ovarian cancer (EOC) growth and their receptor expression is associated with disease outcome. Hormone therapy is frequently used in pretreated EOC, but the magnitude of activity overall and by specific agents or tumor characteristics is unknown. Methods Clinical Benefit Rates (CBR) and deaths from clinical trials of endocrine agents were meta-analyzed. Summary estimates of CBR (SCBR) and Odd Ratio for death (SOR) were calculated according with type of drug, ER and PgR status, platinum resistance, line of therapy, tumor grade and tamoxifen dose. Results Fifty-three trials in 2490 patients were analyzed. Overall, SCBR was 41% (95%CI, 0.34–0.48) for any endocrine treatment, 43% (95%CI, 0.30–0.56) for tamoxifen, 39% (95%CI, 0.29–0.50) for aromatase inhibitors and 37% (95%CI, 0.26–0.48) for progestins. The SCBR for ER + and/or PgR + tumors was 46% (95%CI, 0.34–0.57) versus 37% (95%CI, 0.27–0.48) in tumors with unknown receptors and 55% in platinum sensitive (95%CI, 0.28–0.80) versus 40% (95%CI, 0.29–0.51) in platinum resistant tumors The SOR for death calculated from 6 out of 9 randomized clinical trials (RCTs) showed a reduced mortality with endocrine therapy (SOR = 0.69, 95%CI, 0.50–0.97), with a possible tendency for a greater effect in first line and low grade tumors. The overall quality of the RCTs was low. Conclusions The activity of endocrine therapy in advanced EOC is worth considering and seems to support large properly designed randomized trials in the first treatment of hormone sensitive EOC.

UR - http://www.scopus.com/inward/record.url?scp=85022078849&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85022078849&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2017.06.036

DO - 10.1016/j.ygyno.2017.06.036

M3 - Article

VL - 146

SP - 504

EP - 513

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 3

ER -